{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:47:30Z","timestamp":1789832850656,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,28]]},"DOI":"10.7759\/cureus.55147","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:45:36Z","timestamp":1709135136000},"source":"Crossref","is-referenced-by-count":1,"title":["Delayed Pseudoprogression in Glioblastoma Patients Treated With Tumor-Treating Fields"],"prefix":"10.7759","author":[{"given":"Norihiko","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morito","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092283","article-title":"Permeabilizing cell membranes with electric fields","volume":"13","author":"Aguilar AA","year":"2021","unstructured":"Aguilar AA, Ho MC, Chang E, et al.. Permeabilizing cell membranes with electric fields. Cancers (Basel). 2021, 13:2283. 10.3390\/cancers13092283","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot OL","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, et al.. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014, 370:709-22. 10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert MR","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, et al.. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014, 370:699-708. 10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert MR","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, et al.. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013, 31:4085-91. 10.1200\/JCO.2013.49.6968","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp R","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, et al.. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012, 48:2192-202. 10.1016\/j.ejca.2012.04.011","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp R","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, et al.. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017, 318:2306-16. 10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma D","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W,et.al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008, 9:453-61. 10.1016\/S1470-2045(08)70125-6","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9241-y","article-title":"Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma","volume":"82","author":"Chamberlain MC","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007, 82:81-3. 10.1007\/s11060-006-9241-y","journal-title":"J Neurooncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac194","article-title":"Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a\u00a0POLA network study","volume":"25","author":"Seyve A","year":"2023","unstructured":"Seyve A, Dehais C, Chinot O, et al.. Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a\u00a0POLA network study. Neuro Oncol. 2023, 25:495-507. 10.1093\/neuonc\/noac194","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide","volume":"113","author":"Taal W","year":"2008","unstructured":"Taal W, Brandsma D, de Bruin HG, et al.. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008, 113:405-10. 10.1002\/cncr.23562","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac137","article-title":"First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma","volume":"4","author":"Lazaridis L","year":"2022","unstructured":"Lazaridis L, Bumes E, C\u00e4cilia Spille D, et al.. First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma. Neurooncol Adv. 2022, 4:vdac137. 10.1093\/noajnl\/vdac137","journal-title":"Neurooncol Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor treating fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang E","year":"2018","unstructured":"Chang E, Patel CB, Pohling C, et al.. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 2018, 4:113. 10.1038\/s41420-018-0130-x","journal-title":"Cell Death Discov"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0887","article-title":"The mechanisms of action of tumor treating fields","volume":"82","author":"Moser JC","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, et al.. The mechanisms of action of tumor treating fields. Cancer Res. 2022, 82:3650-8. 10.1158\/0008-5472.CAN-22-0887","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101348","article-title":"Tumor treating fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo","volume":"12","author":"Salvador E","year":"2022","unstructured":"Salvador E, Kessler AF, Domr\u00f6se D, et al.. Tumor treating fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo. Biomolecules. 2022, 12:1348. 10.3390\/biom12101348","journal-title":"Biomolecules"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.193.3.7972799","article-title":"Radiation-induced telangiectasia in the brain simulates cryptic vascular malformations at MR imaging","volume":"193","author":"Gaensler EH","year":"1994","unstructured":"Gaensler EH, Dillon WP, Edwards MS, Larson DA, Rosenau W, Wilson CB. Radiation-induced telangiectasia in the brain simulates cryptic vascular malformations at MR imaging. Radiology. 1994, 193:629-36. 10.1148\/radiology.193.3.7972799","journal-title":"Radiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03076-w","article-title":"Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients","volume":"142","author":"Voss M","year":"2019","unstructured":"Voss M, Franz K, Steinbach JP, et al.. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neurooncol. 2019, 142:161-9. 10.1007\/s11060-018-03076-w","journal-title":"J Neurooncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231798-delayed-pseudoprogression-in-glioblastoma-patients-treated-with-tumor-treating-fields","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:45:41Z","timestamp":1709135141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231798-delayed-pseudoprogression-in-glioblastoma-patients-treated-with-tumor-treating-fields"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.55147","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}